Trials / Completed
CompletedNCT03112577
Study of REGN3500 and Dupilumab in Patients With Asthma
A Randomized, Placebo-controlled, Parallel Panel Study to Assess the Effects of REGN3500, Dupilumab, and Combination of REGN3500 Plus Dupilumab on Markers of Inflammation After Bronchial Allergen Challenge in Patients With Allergic Asthma
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 32 (actual)
- Sponsor
- Regeneron Pharmaceuticals · Industry
- Sex
- All
- Age
- 18 Years – 60 Years
- Healthy volunteers
- Not accepted
Summary
To assess the effects of REGN3500, dupilumab, and REGN3500 plus dupilumab, compared with placebo, on changes in inflammatory gene expression signatures in sputum induced after a bronchial allergen challenge (BAC) in adults with mild allergic asthma, at week 4 after treatment initiation compared with those at screening.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | REGN3500 | Intravenous (IV) use |
| DRUG | Dupilumab | Subcutaneous (SC) use |
| DRUG | Placebo | Matching placebo |
| DRUG | Fluticasone propionate | Inhalation use |
Timeline
- Start date
- 2017-06-15
- Primary completion
- 2019-03-20
- Completion
- 2019-12-09
- First posted
- 2017-04-13
- Last updated
- 2020-01-18
Locations
5 sites across 2 countries: United States, United Kingdom
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03112577. Inclusion in this directory is not an endorsement.